The Clinical Trials website (https://clinicaltrials.gov/) as on 30 August 2017, lists trials for (a) the changes in DUSP1 expression in response to treatment for depression; (b) cross-sectional and longitudinal study of individuals with autism and germline heterozygous PTEN mutations; (c) everolimus drug and neurocognition in PTEN hamartoma tumor syndrome; and (d) DUSP6 expression changes as biomarker in response to non-small cell lung cancer, thyroid cancer, and advanced solid tumor treatments. This evidence concerns the gene DUSP6 and thyroid gland carcinoma.